FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282940111> ?p ?o ?g. }

• W4282940111 endingPage "2306" @default.
• W4282940111 startingPage "2306" @default.
• W4282940111 abstract "At a given estimated glomerular filtration rate (eGFR), individuals who are Black have higher rates of mortality and kidney failure with replacement therapy (KFRT) compared with those who are non-Black. Whether the recently adopted eGFR equations without race preserve racial differences in risk of mortality and KFRT at a given eGFR is unknown.To assess whether eGFR equations with and without race and cystatin C document racial differences in risk of KFRT and mortality in populations including Black and non-Black participants.Retrospective individual-level data analysis of 62 011 participants from 5 general population and 3 chronic kidney disease (CKD) US-based cohorts with serum creatinine, cystatin C, and follow-up for KFRT and mortality from 1988 to 2018.Chronic Kidney Disease Epidemiology Collaboration equation with serum creatinine (eGFRcr with and without race), cystatin C (eGFRcys without race), or both markers (eGFRcr-cys without race).The prevalence of decreased eGFR at baseline and hazard ratios of KFRT and mortality in Black vs non-Black participants were calculated, adjusted for age and sex. Analyses were performed within each cohort and with random-effect meta-analyses of the models.Among 62 011 participants (20 773 Black and 41 238 non-Black; mean age, 63 years; 53% women), the prevalence ratio (95% CI; percent prevalences) of eGFR less than 60 mL/min/1.73 m2 comparing Black with non-Black participants was 0.98 (95% CI, 0.93-1.03; 11% vs 12%) for eGFRcr with race, 0.95 (95% CI, 0.91-0.98; 17% vs 18%) for eGFRcys, and 1.2 (95% CI, 1.2-1.3; 13% vs 11%) for eGFRcr-cys but was 1.8 (95% CI, 1.7-1.8; 15% vs 9%) for eGFRcr without race. During a mean follow-up of 13 years, 8% and 4% of Black and non-Black participants experienced KFRT and 34% and 39% died, respectively. Decreased eGFR was associated with significantly greater risk of both outcomes for all equations. At an eGFR of 60 mL/min/1.73 m2, the hazard ratios for KFRT comparing Black with non-Black participants were 2.8 (95% CI, 1.6-4.9) for eGFRcr with race, 3.0 (95% CI, 1.5-5.8) for eGFRcys, and 2.8 (95% CI, 1.4-5.4) for eGFRcr-cys vs 1.3 (95% CI, 0.8-2.1) for eGFRcr without race. The 5-year absolute risk differences for KFRT comparing Black with non-Black participants were 1.4% (95% CI, 0.2%-2.6%) for eGFRcr with race, 1.1% (95% CI, 0.2%-1.9%) for eGFRcys, and 1.3% (95% CI, 0%-2.6%) for eGFRcr-cys vs 0.37% (95% CI, -0.32% to 1.05%) for eGFRcr without race. Similar patterns were observed for mortality.In this retrospective analysis of 8 US cohorts including Black and non-Black individuals, the eGFR equation without race that included creatinine and cystatin C, but not the eGFR equation without race that included creatinine without cystatin C, demonstrated racial differences in the risk of KFRT and mortality throughout the range of eGFR. The eGFRcr-cys equation may be preferable to the eGFRcr equation without race for assessing racial differences in the risk of KFRT and mortality associated with low eGFR." @default.
• W4282940111 created "2022-06-16" @default.
• W4282940111 creator A5011495488 @default.
• W4282940111 creator A5026846209 @default.
• W4282940111 creator A5032690087 @default.
• W4282940111 creator A5033395115 @default.
• W4282940111 creator A5036188439 @default.
• W4282940111 creator A5041495874 @default.
• W4282940111 creator A5044235150 @default.
• W4282940111 creator A5050973509 @default.
• W4282940111 creator A5054296834 @default.
• W4282940111 creator A5071585977 @default.
• W4282940111 creator A5074978138 @default.
• W4282940111 creator A5078723203 @default.
• W4282940111 creator A5086558284 @default.
• W4282940111 date "2022-06-21" @default.
• W4282940111 modified "2023-10-11" @default.
• W4282940111 title "Association of Estimated GFR Calculated Using Race-Free Equations With Kidney Failure and Mortality by Black vs Non-Black Race" @default.
• W4282940111 cites W1969735455 @default.
• W4282940111 cites W1971658255 @default.
• W4282940111 cites W2005290596 @default.
• W4282940111 cites W2035310230 @default.
• W4282940111 cites W2050869145 @default.
• W4282940111 cites W2051208577 @default.
• W4282940111 cites W2054891539 @default.
• W4282940111 cites W2073063487 @default.
• W4282940111 cites W2103047306 @default.
• W4282940111 cites W2113760558 @default.
• W4282940111 cites W2118625269 @default.
• W4282940111 cites W2123775770 @default.
• W4282940111 cites W2137004892 @default.
• W4282940111 cites W2142172228 @default.
• W4282940111 cites W2143415050 @default.
• W4282940111 cites W2146105386 @default.
• W4282940111 cites W2155965977 @default.
• W4282940111 cites W2168378300 @default.
• W4282940111 cites W2355660319 @default.
• W4282940111 cites W2467227824 @default.
• W4282940111 cites W2475261460 @default.
• W4282940111 cites W2607031541 @default.
• W4282940111 cites W2949004837 @default.
• W4282940111 cites W3042331661 @default.
• W4282940111 cites W3095099370 @default.
• W4282940111 cites W3109310044 @default.
• W4282940111 cites W3111410489 @default.
• W4282940111 cites W3164381515 @default.
• W4282940111 cites W3199923049 @default.
• W4282940111 cites W3200217233 @default.
• W4282940111 cites W4226390647 @default.
• W4282940111 cites W4248927088 @default.
• W4282940111 doi "https://doi.org/10.1001/jama.2022.8801" @default.
• W4282940111 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35667006" @default.
• W4282940111 hasPublicationYear "2022" @default.
• W4282940111 type Work @default.
• W4282940111 citedByCount "20" @default.
• W4282940111 countsByYear W42829401112022 @default.
• W4282940111 countsByYear W42829401112023 @default.
• W4282940111 crossrefType "journal-article" @default.
• W4282940111 hasAuthorship W4282940111A5011495488 @default.
• W4282940111 hasAuthorship W4282940111A5026846209 @default.
• W4282940111 hasAuthorship W4282940111A5032690087 @default.
• W4282940111 hasAuthorship W4282940111A5033395115 @default.
• W4282940111 hasAuthorship W4282940111A5036188439 @default.
• W4282940111 hasAuthorship W4282940111A5041495874 @default.
• W4282940111 hasAuthorship W4282940111A5044235150 @default.
• W4282940111 hasAuthorship W4282940111A5050973509 @default.
• W4282940111 hasAuthorship W4282940111A5054296834 @default.
• W4282940111 hasAuthorship W4282940111A5071585977 @default.
• W4282940111 hasAuthorship W4282940111A5074978138 @default.
• W4282940111 hasAuthorship W4282940111A5078723203 @default.
• W4282940111 hasAuthorship W4282940111A5086558284 @default.
• W4282940111 hasBestOaLocation W42829401112 @default.
• W4282940111 hasConcept C107130276 @default.
• W4282940111 hasConcept C126322002 @default.
• W4282940111 hasConcept C144024400 @default.
• W4282940111 hasConcept C149923435 @default.
• W4282940111 hasConcept C159641895 @default.
• W4282940111 hasConcept C201903717 @default.
• W4282940111 hasConcept C207103383 @default.
• W4282940111 hasConcept C2778653478 @default.
• W4282940111 hasConcept C2779548226 @default.
• W4282940111 hasConcept C2780306776 @default.
• W4282940111 hasConcept C2908647359 @default.
• W4282940111 hasConcept C44249647 @default.
• W4282940111 hasConcept C59822182 @default.
• W4282940111 hasConcept C71924100 @default.
• W4282940111 hasConcept C72563966 @default.
• W4282940111 hasConcept C76509639 @default.
• W4282940111 hasConcept C86803240 @default.
• W4282940111 hasConcept C99454951 @default.
• W4282940111 hasConceptScore W4282940111C107130276 @default.
• W4282940111 hasConceptScore W4282940111C126322002 @default.
• W4282940111 hasConceptScore W4282940111C144024400 @default.
• W4282940111 hasConceptScore W4282940111C149923435 @default.
• W4282940111 hasConceptScore W4282940111C159641895 @default.
• W4282940111 hasConceptScore W4282940111C201903717 @default.
• W4282940111 hasConceptScore W4282940111C207103383 @default.
• W4282940111 hasConceptScore W4282940111C2778653478 @default.

• next